We just received data on a new analyst forecast for $MBX. Oppenheimer gave a rating of 'Outperform' for $MBX.
$MBX Analyst Ratings
Wall Street analysts have issued reports on $MBX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 07/16/2025
- JMP Securities issued a "Market Outperform" rating on 04/10/2025
- Guggenheim issued a "Buy" rating on 04/10/2025
To track analyst ratings and price targets for $MBX, check out Quiver Quantitative's $MBX forecast page.
$MBX Price Targets
Multiple analysts have issued price targets for $MBX recently. We have seen 3 analysts offer price targets for $MBX in the last 6 months, with a median target of $38.0.
Here are some recent targets:
- Trevor Allred from Oppenheimer set a target price of $38.0 on 07/16/2025
- Jonathan Wolleben from JMP Securities set a target price of $38.0 on 04/10/2025
- Seamus Fernandez from Guggenheim set a target price of $44.0 on 04/10/2025
$MBX Insider Trading Activity
$MBX insiders have traded $MBX stock on the open market 10 times in the past 6 months. Of those trades, 10 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MBX stock by insiders over the last 6 months:
- ADVISORS LLC ORBIMED has made 4 purchases buying 190,672 shares for an estimated $2,020,755 and 0 sales.
- CARL L GORDON has made 4 purchases buying 190,672 shares for an estimated $2,020,755 and 0 sales.
- P. KENT HAWRYLUK (President & CEO) purchased 50,000 shares for an estimated $534,500
- ORA H. PESCOVITZ purchased 7,693 shares for an estimated $45,311
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
